MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma

Fernández-Rodríguez, C ; Bellosillo, B ; García-García, M ; Sánchez-González, B ; Gimeno, E ; Vela, M C ; Serrano, S ; Besses, C ; Salar, A

Resumen: Diffuse large B-cell lymphoma (DLBCL) encompasses an aggressive and heterogeneous group of malignancies. Gene expression profiling (GEP) unraveled two main subtypes based on their putative cell of origin named germinal center B-cell-like (GCB) and activated B-cell-like (ABC), with specific genetic alterations and different clinical outcome. Recent studies have reported several somatic mutations in the myeloid differentiation primary response gene 88 (MYD88) affecting B-cell lymphomas. Among them, the leucine to proline exchange at position 265 (L265P) is the most recurrent and biologically potent MYD88 variation, being found in about 30% of ABC-DLBCL but uncommon in GCB-DLBCL. Here, we have investigated the occurrence of MYD88 L265P mutation in adult patients with DLBCL and its relation to clinical and biological characteristics, including patients’ outcome.

Idioma: Inglés

DOI: 10.1038/leu.2014.184

Año: 2014

Publicado en: Leukemia 28, 10 (2014), 2104-2106
ISSN: 0887-6924

Factor impacto JCR: 10.431 (2014)

Categ. JCR: ONCOLOGY rank: 9 / 209 = 0.043 (2014) - Q1 - T1
Categ. JCR: HEMATOLOGY rank: 3 / 68 = 0.044 (2014) - Q1 - T1

Tipo y forma: (Versión definitiva)